# Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

> **NCT04311697** · PHASE2,PHASE3 · COMPLETED · sponsor: **APR Applied Pharma Research s.a.** · enrollment: 203 (actual)

## Conditions studied

- Critical COVID-19 With Respiratory Failure
- Acute Respiratory Distress Syndrome (ARDS)
- Corona Virus Infection
- Acute Lung Injury

## Interventions

- **DRUG:** Aviptadil by intravenous infusion + standard of care
- **DRUG:** Normal Saline Infusion + standard of care

## Key facts

- **NCT ID:** NCT04311697
- **Lead sponsor:** APR Applied Pharma Research s.a.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-02-22
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311697, "Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04311697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*